Evaluation of two health status measures in adults with growth hormone deficiency

Clare Bradley, C V McMillan, J Gibney, D L Russell-Jones and P H Sönksen


Clare Bradley, C V McMillan, J Gibney, D L Russell-Jones and P H Sönksen (2003) Evaluation of two health status measures in adults with growth hormone deficiency. Clinical Endocrinology, 58 (4).

Our Full Text Deposits

Full text access: Open

Full Text - 89.69 KB

Links to Copies of this Item Held Elsewhere


Objective: To evaluate the psychometric properties of two health status measures for adults with growth hormone deficiency (GHD): Nottingham Health Profile (NHP) and Short Form Health Survey (SF-36).
Design: (1) A cross-sectional survey of adults with treated or untreated GHD, to assess reliability and validity of the questionnaires. (2) A randomised, placebo-controlled study of 3 months’ GH withdrawal from GH-treated adults, to assess the questionnaires’ sensitivity to change.
Patients: (1) Cross-sectional survey of 157 patients with severe GHD (peak GH < 10mU/L on provocative testing), mean age 48.9 (range 23-70), who had either received GH-replacement therapy for at least 6 months immediately prior to the study, or had not received GH treatment in the previous 6 months. (2) GH treatment was withdrawn from 12 of 21 GH-treated adults, all with severe GHD (peak GH < 7.7 mU/L on provocative testing), mean age 44.9 (range 25–68).
Measurements: The NHP and SF-36 were used once in the cross-sectional survey, but twice in the GH-withdrawal study, at baseline and end-point (after 3 months).
Results: (1) Cross-sectional survey. Both questionnaires had high internal consistency reliability with subscale Cronbach’s alphas of > 0.73 (NHP) and > 0.78 (SF 36). Calculation of a NHP Total score, occasionally reported in the literature, was shown to be inadvisable. Overall, patients with GHD were found to have significantly worse perceived functioning than the UK general population in SF 36 subscales of General Health, Pain, Social Functioning, Role-Emotional, Role-Physical, and Vitality. Whilst neither questionnaire found significant differences between GH-treated and non-GH-treated patients, there were correlations with duration of GH treatment (p < 0.01) for GH-treated patients, in SF 36 Mental Health [r = 0.29, N = 87] and SF-36 Vitality [r = 0.33, N = 88], indicating improvement with increasing treatment duration. The SF-36 was also more sensitive than the NHP to sex differences: men had significantly better health status compared with women (p < 0.05) in all SF-36 subscales but Mental Health, but only in one NHP subscale (Physical Mobility). (2) GH-withdrawal study. Significant between group differences in change were found in SF 36 General Health [t(17) = 2.76, p = 0.013, 2-tailed] and SF-36 Mental Health [t(17) = 2.41, p = 0.027, 2-tailed]: patients withdrawn from GH reported reduced general health and mental health at end-point. The NHP found no significant change.
Conclusions: The SF-36 is a better measure than the NHP of health status of people with GHD, owing to its greater discriminatory power with ability to detect lesser degrees of disability. It also has superior sensitivity to some sub-group differences and superior sensitivity to change than the NHP. The SF-36 is highly acceptable to respondents, and has very good internal consistency reliability. The SF-36 is recommended to measure the health status of adults with GHD.

Information about this Version

This is a Published version
This version's date is: 2003
This item is not peer reviewed

Link to this Version


Item TypeJournal Article
TitleEvaluation of two health status measures in adults with growth hormone deficiency
AuthorsBradley, Clare
McMillan, C V
Gibney, J
Russell-Jones, D L
Sönksen, P H
Uncontrolled Keywordsgrowth hormone deficiency, functioning, health, questionnaire, treatment, gender differences
DepartmentsFaculty of Science\Psychology



Deposited by () on 23-Dec-2009 in Royal Holloway Research Online.Last modified on 12-May-2010


Anderson, R.M., Fitzgerald, J.T., Wisdom, K., Davis, W.K. & Hiss, R.G. (1997) A comparison of global versus disease-specific quality-of-life measures in patients with NIDDM. Diabetes Care 20, 299-305.
Attanasio, A.F., Lamberts, S.W.J., Matranga, A.M.C., Birkett, M.A., Bates, P.C., Valk, N.K., Hilsted, J., Bengtsson, B.A. & Strasburger, C.J. (1997) Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Journal of Clinical Endocrinology and Metabolism 82, 82-88.
Baum, H.B.A., Katznelson, L., Sherman, J.C., Biller, B.M.K., Hayden, D.L., Schoenfeld, D.A., Cannistraro, K.E. & Klibanski, A. (1998) Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH deficiency. Journal of Clinical Endocrinology and Metabolism 83, 3184-3189.
Benbow, S.J., Wallymahmed, M.E. & MacFarlane, I.A. (1998) Diabetic peripheral neuropathy and quality of life. Qjm-Monthly Journal of the Association of Physicians 91, 733-737.
Bowling, A. (1991) Measuring health. Open University Press, Buckingham.
Bradley, C. (1994) The Well-being Questionnaire. In: Handbook of Psychology and Diabetes: a guide to psychological measurement in diabetes research and practice (ed. C. Bradley), pp. 89-109. Harwood Academic Publishers, Chur, Switzerland.
Bradley, C. (1999) Achieving accessibility with quality: questionnaire measurement of condition-specific individualised quality of life. Proceedings of the British Psychological Society 7, 143.
Bradley, C. (2001) Importance of differentiating health status from quality of life. Lancet 357, 7-8.
Brazier, J.E., Harper, R., Jones, N.M.B., Ocathain, A., Thomas, K.J., Usherwood, T. & Westlake, L. (1992) Validating the SF-36 Health Survey Questionnaire - new outcome measure for primary care. British Medical Journal 305, 160-164.
Burman, P., Broman, J.E., Hetta, J., Wiklund, I., Erfurth, E.M., Hagg, E. & Karlsson, F.A. (1995) Quality-of-Life in adults with Growth-Hormone (GH) Deficiency - Response to treatment with recombinant human GH in a placebo-controlled 21-month trial. Journal of Clinical Endocrinology and Metabolism 80, 3585-3590.
Burney, R.E., Jones, K.R., Christy, B. & Thompson, N.W. (1999) Health status improvement after surgical correction of primary hyperparathyroidism in patients with high and low preoperative calcium levels. Surgery 125, 608-614.
Carroll, P.V., Christ, E.R. & Growth Hormone Research Society Scientific Committee (1998) Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Journal of Clinical Endocrinology and Metabolism 83, 382-395.
Carroll, P.V., Littlewood, R., Weissberger, A.J., Bogalho, P., McGauley, G., Sönksen, P.H. & Russell-Jones, D.L. (1997) The effects of two doses of replacement growth hormone on the biochemical, body composition and psychological profiles of growth hormone-deficient adults. European Journal of Endocrinology 137, 146-153.
Costello, C.G. & Devins, G.M. (1998) Two stage screening for stressful life events and chronic difficulties. Canadian Journal of Behavioral Science 20, 85-92.
Cronbach, L.J. (1951) Coefficient alpha and the internal structure of tests. Psychometrika 16, 297-334.
Cuneo, R.C., Judd, S., Wallace, J.D., Perry-Keene, D., Burger, H., Lim-Tio, S., Strauss, B., Stockigt, J., Topliss, D., Alford, F., Hew, L., Bode, H., Conway, A., Handelsman, D., Dunn, S., Boyages, S., Cheung, N.W. & Hurley, D. (1998) The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism 83, 107-116.
Fava, G.A., Sonino, N., Morphy, M.A. (1993) Psychosomatic view of endocrine disorders. Psychotherapy and Psychosomatics. 59, 20-33.
Garratt, A.M., Ruta, D.A., Abdalla, M.I., Buckingham, J.K. & Russell, I.T. (1993) The SF-36 Health Survey Questionnaire - an outcome measure suitable for routine use within the NHS. British Medical Journal 306, 1440-1444.
Green, S.B., Salkind, N.J. & Akey, T.M. (1997) Using SPSS for Windows: Analyzing and understanding data. Prentice-Hall, New Jersey.
Hakkaart-van Roijen, L., Beckers, A., Stevenaert, A. & Rutten, F.F.H. (1998) The burden of illness of hypopituitary adults with growth hormone deficiency. PharmacoEconomics 14, 395-403.
Hunt, S.M., McEwen, J. & McKenna, S.P. (1985) Measuring health status - a new tool for clinicians and epidemiologists. Journal of the Royal College of General Practitioners 35, 185-188.
Hunt, S.M. & McKenna, S.P. (1989) The Nottingham Health Profile. In: European Guide to the Nottingham Health Profile. The European Group for Quality of Life and Health Measurement.
Hunt, S.M. & McKenna, S.P. (1992) A British adaptation of the General Well-being Index: a new tool for clinical research. British Journal of Medical Economics 2, 49-60.
Hunt, S.M., McKenna, S.P. & Doward, L.C. (1993) Preliminary report on the development of a disease-specific instrument for assessing quality-of-life of adults with growth hormone deficiency. Acta Endocrinologica 128, 37-40.
Kenny, A.M., Bellantonio, S., Gruman, C.A., Acosta, R.D. & Prestwood, K.M. (2002) Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels. Journals of Gerontology Series a-Biological Sciences and Medical Sciences 57, M321-M325.
Kline, P. (1993) A handbook of test construction. Routledge, London.
Kline, P. (1994) An easy guide to factor analysis. Routledge, London.
Lovas, K., Loge, J.H. & Husebye, E.S. (2002) Subjective health status in Norwegian patients with Addison's disease. Clinical Endocrinology 56, 581-588.
Mardh, G., Lundin, K., Borg, G., Jonsson, B. & Lindeberg, A. (1994) Growth hormone replacement therapy in adult hypopituitary patients with growth hormone deficiency: combined data from 12 European placebo-controlled clinical trials. Endocrinology and Metabolism 1, (Suppl.A), 43-49.
McGauley, G., Cuneo, R.C., Salomon, F. & Sönksen, P. (1990) Psychosocial well being before and after growth hormone treatment in adults with growth hormone deficiency. Hormone Research 33, (Suppl. 4), 52-54.
McMillan, C. & Bradley, C. (2000) A comparison of the psychometric properties of quality of life and related measures (GWBI, W-BQ12, NHP, SF-36 and HDQoL) for use in research into adult growth hormone deficiency (GHD). Quality of Life Research 9, Abstract 1352, p1324.
McMillan, C.V. (2001) A psychometric evaluation of measures of quality of life and related health outcomes in adults with growth hormone deficiency. (PhD Thesis). Royal Holloway, University of London.
McMillan, C.V., Gibney, J., Russell-Jones, D.L., Sönksen, P.H. & Bradley, C. (2001) Psychological effects of withdrawal of growth hormone (GH) therapy from GH-deficient adults. Endocrine Abstracts 1, P111.
O'Malley, B., Hickey, J. & Nevens, E. (2000) Thyroid dysfunction - weight problems and the psyche: the patients' perspective. Journal of Human Nutrition and Dietetics 13, 243-248.
Powrie, J., Weissberger, A. & Sönksen, P. (1995) Growth hormone replacement therapy for growth hormone-deficient adults. Drugs 49, 656-663.
Ryan, N. & Rosner, A. (2001) Quality of life and costs associated with micronized progesterone and medroxyprogesterone acetate in hormone replacement therapy for nonhysterectomized, postmenopausal women. Clinical Therapeutics 23, 1099-1115.
Smith, K.W., Avis, N.E. & Assmann, S.F. (1999) Distinguishing between quality of life and health status in quality of life research: A meta-analysis. Quality of Life Research 8, 447-459.
Sonino, N. & Fava, G.A. (2001) Psychiatric disorders associated with Cushing's syndrome. Epidemiology, pathophysiology and treatment. CNS Drugs 15, 361-373.
Sönksen, P., Cuneo, R.C., Salomon, F., McGauley, G., Wiles, C.M., Wilmshurst, P., Byrne, C., Hesp, R., Lowy, C. & Weissberger, A. (1991) Growth-Hormone therapy in adults with growth-hormone deficiency. Acta Paediatrica Scandinavica 379, (Suppl.):139-146.
Tabachnik, B.G. & Fidell, L.S. (1983) Using multivariate statistics. 1st edn. Harper and Row, New York.
Todd, C. & Bradley, C. (1994) Evaluating the design and development of psychological scales. In: Handbook of psychology and diabetes: a guide to psychological measurement in diabetes research and practice (ed. C. Bradley), pp. 89-109. Harwood Academic Publishers, Chur, Switzerland.
Wallymahmed, M.E., Baker, G.A., Humphris, G., Dewey, M. & MacFarlane, I.A. (1996) The development, reliability and validity of a disease specific quality of life model for adults with growth hormone deficiency. Clinical Endocrinology 44, 403-411.
Wallymahmed, M.E., Foy, P., Shaw, D., Hutcheon, R., Edwards, R.H.T. & MacFarlane, I.A. (1997) Quality of life, body composition and muscle strength in adult growth hormone deficiency: the influence of growth hormone replacement therapy for up to 3 years. Clinical Endocrinology 47, 439-446.
Ware, J.E. & Sherbourne, C.D. (1992) The MOS 36-Item Short-Form Health Survey (SF-36). 1. Conceptual framework and item selection. Medical Care 30, 473-483.
Whitehead, H.M., Boreham, C., McIlrath, E.M., Sheridan, B., Kennedy, L., Atkinson, A.B. & Hadden, D.R. (1992) Growth-hormone treatment of adults with growth-hormone deficiency - Results of a 13-month placebo controlled cross-over study. Clinical Endocrinology 36, 45-52.
Wiren, L., Bengtsson, B.A. & Johannsson, G. (1998) Beneficial effects of long-term GH replacement therapy on quality of life in adults with GH deficiency. Clinical Endocrinology 48, 613-620.